Clinical Trial Update: A Pilot Study to Evaluate the Role of High-dose Ranibizumab (2.0mg) in the Management of AMD in Patients With Persistent/Recurrent Macular Fluid Less Than 30 Days Following Treatment With Intravitreal Anti-VEGF Therapy (the LAST Study) [Phase 1, Phase 2]

View source ↗

Summary

Pilot Phase 1/2 study evaluating high-dose ranibizumab (2.0 mg) for persistent or recurrent macular fluid in age-related macular degeneration after prior anti-V…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• Lucentis (ranibizumab)

Snippet

Sponsor: Vitreous -Retina- Macula Consultants of New York | Conditions: Age Related Macular Degeneration | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2017-10-06